IQVIA (NYSE:IQV) Sets New 1-Year High on Better-Than-Expected Earnings

IQVIA Holdings Inc. (NYSE:IQV) shares hit a new 52-week high during mid-day trading on Tuesday after the company announced better than expected quarterly earnings. The stock traded as high as $247.72 and last traded at $244.5570, with a volume of 775068 shares trading hands. The stock had previously closed at $213.22.

The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same quarter in the prior year, the firm posted $2.81 earnings per share. IQVIA’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS.

IQVIA declared that its board has approved a share repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board believes its stock is undervalued.

Key IQVIA News

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Q2 earnings and revenue exceeded estimates. IQVIA reported adjusted earnings of $3.15 per share, above the $3.02-$3.03 analyst consensus and up from $2.81 a year earlier. Revenue increased 8.7% year over year to $4.37 billion, surpassing the $4.30 billion estimate. IQVIA Holdings Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management raised its full-year profit forecast. IQVIA now expects fiscal 2026 earnings per share of $12.80-$13.00, above the $12.57 consensus estimate. Revenue guidance of $17.3-$17.5 billion was also maintained at or above expectations, signaling confidence in demand and execution. IQVIA Raises Annual Profit Forecast on Clinical Research Demand
• Positive Sentiment: Clinical research demand and backlog are supporting growth. Reports highlighted sustained customer demand and a ballooning backlog, which could provide future revenue visibility for IQVIA’s clinical research and healthcare intelligence businesses. IQVIA Stocks Rises on 2Q Gains and Ballooning Backlog
• Neutral Sentiment: IQVIA’s shares are near their 52-week high after the results, while the stock trades at roughly 30 times earnings and carries a debt-to-equity ratio of about 2.2. The strong outlook is supportive, but the valuation and leverage may limit further upside if growth or margins disappoint.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Mizuho increased their price target on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a research report on Thursday, July 9th. HSBC restated a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a report on Monday, July 6th. Finally, Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Thirteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $225.71.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of IQV. Ameliora Wealth Management Ltd. purchased a new stake in shares of IQVIA in the 4th quarter valued at $25,000. Financial Freedom LLC purchased a new position in IQVIA during the 1st quarter valued at about $25,000. Ascentis Independent Advisors purchased a new position in IQVIA during the 1st quarter valued at about $25,000. International Assets Investment Management LLC acquired a new position in IQVIA in the 4th quarter valued at about $27,000. Finally, Gilpin Wealth Management LLC purchased a new stake in IQVIA during the fourth quarter worth about $27,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Price Performance

The company has a market capitalization of $40.75 billion, a PE ratio of 30.25, a price-to-earnings-growth ratio of 1.87 and a beta of 1.20. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The stock’s 50 day simple moving average is $189.02 and its 200-day simple moving average is $186.85.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.